Neuland Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
NEULANDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.4 pts less than Nifty Smallcap 250 and 1.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Neuland Laboratories reported Q1 FY26 standalone revenue from operations of ₹29,275 lakhs, down about 33% from ₹43,960 lakhs in Q1 FY25. Standalone profit after tax fell sharply to ₹1,371 lakhs from ₹9,834 lakhs a year ago, though the prior year quarter included an exceptional gain of ₹2,063 lakhs from the transfer of an investment property in Hyderabad. On a consolidated basis, revenue was ₹29,275 lakhs with PAT of ₹1,390 lakhs and EPS of ₹10.83 (vs ₹76.28 in Q1 FY25). MSKA & Associates issued an unqualified limited review report with no qualifications or emphasis of matter.
The steep year-on-year decline in both revenue and profit is a negative signal, though the Q1 FY25 base was inflated by a one-time property gain. Investors should focus on the underlying operational weakness — revenue and core earnings have contracted meaningfully, which may weigh on the stock in the near term.